Improving the effectiveness of cervical cancer screening: Managing positive high-risk human papillomavirus results

被引:1
|
作者
Tay, Sun Kuie [1 ]
机构
[1] Singapore Gen Hosp, Dept Obstet & Gynecol, 20 Coll Rd, Singapore 169856, Singapore
关键词
cervical screening; CIN2+; colposcopy; high-grade lesions; HPV positivity; HPV regression; TERM-FOLLOW-UP; CYTOLOGY; PROGRAM; RECALL; WOMEN;
D O I
10.47102/annals-acadmedsg.2023329
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Good compliance of the management of abnormal results is important for effective cervical screening. This study investigated the rate of surveillance and follow-up outcomes for human papillomavirus (HPV)-positive women in cervical screening. Method: Women on surveillance by repeat HPV testing were identified in a prospectively managed database. Data retrieved included women's age, country residence status, history of colposcopy, HPV-DNA status on the first and repeat tests, dates of follow-up during the 5 years since the initial screening, and histological diagnosis of cervical lesions. The main outcome measures were compliance rate for repeat HPV testing, regression and persistence rates of HPV subtypes, and detection rate of high-grade lesions (CIN2+). Results: This analysis included 680 residents in the community, mean age 44.8 (95% confidence interval 20.1-69.5) years. The compliance rate of repeat testing was 28.2% at 12 months and, cumulatively, 42.8% for the entire 5-year follow-up period. The rates were unaffected by age (P=0.5829) nor prior colposcopy (P=0.1607). There were 5 (1.7%) cases of CIN2+ detected. Of 391 women on longitudinal follow-up, 194 (60.8%) cleared their HPV infection. Some women with multiple HPV infection cleared 1 but not the other subtype(s). Thus, the regression rate was 90.3% for HPV-16, 87.0% for HPV-18 and 65.2% for HPV-12-others (P=0.0001). The annualised HPV regression rates were similar for HPV subtypes and for each follow-up year. Conclusion: Surveillance of HPV positivity is clinically important for detecting high-grade lesions. Despite a high regression rate of HPV, surveillance hesitancy is a serious weakness in routine cervical screening.
引用
收藏
页码:342 / 351
页数:10
相关论文
共 50 条
  • [1] High-risk Human Papillomavirus Testing for Cervical Cancer Screening
    Totten, Stephanie P. S.
    Romero, Joan Miguel
    [J]. JAMA ONCOLOGY, 2021, 7 (07) : 1066 - 1067
  • [2] Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Quebec, Canada
    Vijayaraghavan, Arthi
    Efrusy, Molly B.
    Mayrand, Marie-Helene
    Santas, Christopher C.
    Goggin, Patricia
    [J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2010, 101 (03): : 220 - 225
  • [3] Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment
    Stuebs, Frederik A.
    Koch, Martin C.
    Dietl, Anna K.
    Adler, Werner
    Geppert, Carol
    Hartmann, Arndt
    Knoell, Antje
    Beckmann, Matthias W.
    Mehlhorn, Grit
    Schulmeyer, Carla E.
    Gass, Paul
    [J]. DIAGNOSTICS, 2022, 12 (07)
  • [4] High-risk human papillomavirus test a good option for cervical cancer screening
    Printz, Carrie
    [J]. CANCER, 2018, 124 (24) : 4591 - 4591
  • [5] High-risk Human Papillomavirus Testing for Cervical Cancer Screening-Reply
    Dang, Le
    Qiao, Youlin
    Lang, Jinghe
    [J]. JAMA ONCOLOGY, 2021, 7 (07) : 1067 - 1068
  • [6] Cost-effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in Québec, Canada
    Arthi Vijayaraghavan
    Molly B. Efrusy
    Marie-Hélène Mayrand
    Christopher C. Santas
    Patricia Goggin
    [J]. Canadian Journal of Public Health, 2010, 101 : 220 - 225
  • [7] Effectiveness of high-risk human papillomavirus genotyping for cervical cancer screening. A multicentre screening cohort study in rural China
    Yu, Yan-Qin
    Jiang, Ming-Yue
    Zhang, Xun
    Pan, Qin-Jing
    Dang, Le
    Feng, Rui-Mei
    Ali, Nasra Mohamoud
    Chen, Wen
    Qiao, You -Lin
    [J]. ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2024, 47 (02)
  • [8] Self-sampling for high-risk human papillomavirus detection: future cervical cancer screening?
    Daponte, Alexandros
    Pournaras, Spyros
    Tsakris, Athanassios
    [J]. WOMENS HEALTH, 2014, 10 (02) : 115 - 118
  • [9] Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States Is It Time?
    Flanagan, Melina B.
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (06) : 688 - 692
  • [10] Cervical Cancer Screening in Postmenopausal Women: Is It Time to Move Toward Primary High-Risk Human Papillomavirus Screening?
    Kiff, Jaime M.
    Cotter, Madisen
    Munro, Elizabeth G.
    Leonard, Molly E.
    Morgan, Terry K.
    Bruegl, Amanda S.
    [J]. JOURNAL OF WOMENS HEALTH, 2021, 30 (07) : 972 - 978